Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2025

Okada Asuka, Sakata Yoshihiko, Oya Yuko, Sakata Shinya, Yamaguchi Teppei, Tamiya Motohiro, Suzuki Hidekazu, Shibaki Ryota, Yokoyama Toshihide, Matsumoto Hirotaka, Otsuki Taiichiro, Sato Yuki, Uchida Junji, Saito Go, Tsukita Yoko, Inaba Megumi, Ikeda Hideki, Arai Daisuke, Maruyama Hirotaka, Hara Satoshi, Tsumura Shinsuke, Sakagami Takuro

Abstract excerpt

INTRODUCTION: Osimertinib is a highly effective first-line treatment for advanced epithelial growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). With its expanded perioperative use, the long-term risk of cardiotoxicity merits investigation. We assessed the occurrence and risk factors of QT prolongation and cardiac dysfunction in patients with NSCLC treated with first-line...

Read the complete abstract on PubMed

Topics

Humans
Female
Male
Acrylamides
Cardiotoxicity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Aniline Compounds

Retrospective Studies

Aged

Carcinoma, Non-Small-Cell Lung

Middle Aged

Lung Neoplasms

Risk Factors

Mutation

Aged, 80 and over

ErbB Receptors

Antineoplastic Agents

Electrocardiography

Protein Kinase Inhibitors

Source

Identifiers

PMID: 40413921
DOI: 10.1016/j.lungcan.2025.108589

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.PMID 40413921Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.Semantic proximity Read ↗

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.Semantic proximity Read ↗

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.